Hemophilia B
Hemophilia B is a rare genetic bleeding disorder that impairs the blood’s ability to clot properly.
Search results for:
Biomarin plans to sell rights to hemophilia A therapy Roctavian
Biomarin Pharmaceutical is looking to sell off rights to Roctavian (valoctocogene roxaparvovec-rvox), its approved gene therapy for hemophilia A. “As we focus on the business units aligned with our strategic priorities, today we are announcing the decision to pursue options to divest Roctavian and remove it from…
The importance of meeting halfway in hemophilia care
I have a friend from middle school who has a special place in my heart. We call each other “friends of a lifetime.” Years can pass without us speaking to each other, but we pick up as if no time has passed at all. I am part of her family…
Surgical planning is an absolute must when you have hemophilia
Several years ago, when I was checking some incisions about a week after I had a surgical procedure, I discovered gobs of red, gelatinous goo. No scabs had formed over the incisions like they were supposed to. I have hemophilia, so thankfully, I made it through the surgery safely,…
October 31, 2025
by Susie Strachan
Hemophilia A overview
Hemophilia A is a rare genetic disorder that affects the blood’s ability to clot properly. It is the most common form of hemophilia, responsible for 80% of all cases.
October 31, 2025
by Andrea Lobo, PhD
Mim8 for hemophilia
Mim8 (denecimig) is an antibody therapy being developed to prevent or reduce the frequency of bleeding episodes in people with hemophilia A, with or without neutralizing antibodies (inhibitors).
October 30, 2025
by Margarida Maia, PhD
Hemgenix (etranacogene dezaparvovec) for hemophilia
Hemgenix (etranacogene dezaparvovec), formerly known as AMT-061 and EtranaDez, is a gene therapy given as a one-time intravenous (into-the-vein) infusion to treat bleeding episodes in hemophilia B.